Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

23 Sept 2021

Abstract excerpt

Immune checkpoint therapy (ICT) provides substantial clinical benefits to cancer patients, but a large proportion of cancers do not respond to ICT. To date, the genomic underpinnings of primary resistance to ICT remain elusive. Here, we performed immunogenomic analysis of data from TCGA and clinical trials of anti-PD-1/PD-L1 therapy, with a particular focus on homozygous deletion of 9p21.3 (9p21 loss), one of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34556668
DOI: 10.1038/s41467-021-25894-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapyPMID 34556668Read ↗

All is not lost: learning from 9p21 loss in cancerSemantic proximity Read ↗

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer typesSemantic proximity Read ↗

A Multi-Omics Analysis of an Exhausted T Cells’ Molecular Signature in Pan-CancerSemantic proximity Read ↗

Characterization of Exhausted T Cell Signatures in Pan-Cancer SettingsSemantic proximity Read ↗

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.Semantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Somatic 9p24.1 alterations in HPV – head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activitySemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancersSemantic proximity Read ↗

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapySemantic proximity Read ↗

Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacySemantic proximity Read ↗

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.